drugset / Trial / NCT02425852

A Randomized, Multicenter Open Label Study Comparing Early Administration of Azathioprine Plus IFX to Steroids Plus Azathioprine for Acute Severe Colitis

NCT02425852

RandomizedParallel-groupOpen-labelTreatment

Summary

PHASE : IV TYPE OF STUDY : With direct benefit. DESCRIPTIVE : Multicentre, randomized, open label study. INCLUSION CRITERIA : Acute severe ulcerative colitis. OBJECTIVES : To compare the efficacy and safety of early administration of the combination therapy with infliximab and azathioprine with steroids and azathioprine in patients with acute severe ulcerative colitis treated with intravenous steroids. STUDY TREATMENTS : All patients : Intravenous steroids (0.8 mg/kg/day of methylprednisolone or equivalent) for 5 days. Combination therapy arm: Infliximab 5 mg/kg plus Azathioprine 2-2.5 mg/kg/day. Azathioprine arm: Steroids tapering for 3 months and Azathioprine 2-2.5 mg/kg/day.

Timeline

Start
2016-12
Primary completion
2022-06
Completion
2023-01

Drugs

EvaluationDrugModalityDoseRoute
Comparator Azathioprine Small molecule 2.5 mg/kg
Comparator Infliximab Monoclonal antibody 5 mg/kg
Comparator Prednisolone Other / unclassified 1 mg/kg Oral
Comparator Prednisolone Other / unclassified 40 mg Oral
Comparator Prednisolone Other / unclassified 60 mg Oral
Comparator Hydrocortisone Other / unclassified

Indications